CyFlow™ CD13 PE-DyLight™ 594
| Alternative Name: | APN , gp150 |
| Antigen: | CD13 |
| Application: | Flow cytometry |
| Clonality: | monoclonal |
| Clone: | WM15 |
| Emission Maximum: | 618 nm |
| Excitation Maximum: | 593 nm |
| Field of Interest: | Immunophenotyping |
| Format/Fluorochrome: | PE-DyLight™ 594 |
| Isotype: | IgG1 |
| Laser: | Blue , Green, Yellow |
| Regulatory Status: | CE IVD |
| Source Species: | Mouse |
| Target Species: | Human |
| Product number: | BY583888 |
CE IVD
| HLDA Workshop | HLDA III—WS Code M 213 HLDA IV—WS Code M 44 HLDA IV—WS Code M 209 HLDA V—WS Code M MA191 |
| Concentration Unit | µg/mL |
| Concentration | 80 |
| Quantity | 100 tests |
| Volume | 1.0 mL |
| Immunogen | Human Acute Myelogenous Leukemia (AML) cells |
| Background Information | CD13 (APN; aminopeptidase N) is a 150 kDa type II transmembrane zinc-binding ectopeptidase expressed on various cell types. This metalloprotease preferentially catalyzes removal of neutral amino acids from small peptides, thus activating or inactivating bioactive peptides. CD13 has also role in extracellular matrix degradation, antigen processing and signal transduction, is important in inflammatory responses, regulates intercellular contact, cell motility and vascularization. CD13 is involved in protection of leukemic cells against apoptosis and its expression associated with poor prognosis of carcinomas. |
| Antigen Distribution | CD13 (APN, gp150) is a 150 kDa type II transmembrane zinc-binding ectopeptidase expressed on various cell types. This metalloprotease preferentially catalyzes removal of neutral amino acids from small peptides. |
| Usage | CE IVD usage Placeholder |
| Storage Buffer | The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide and 0.2% (w/v) BSA. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
| Bradstock KF, Favaloro EJ, Kabral A, Kerr A, Hughes WG, Berndt MC, Musgrove E: Human myeloid differentiation antigens identified by monoclonal antibodies: expression on leukemic cells. Pathology. 1985 Jul; 17(3):392‑9. < PMID: 3865147 > | Bradstock KF, Favaloro EJ, Kabral A, Kerr A, Hughes WG, Musgrove E: Myeloid progenitor surface antigen identified by monoclonal antibody. Br J Haematol. 1985 Sep; 61(1):44136. < PMID: 4052321 > | McMichael AJ, Beverley PCL, Cobbold S, et al (Eds): Leucocyte Typing III, White Cell Differentiation Antigens. Oxford University Press, Oxford. 1987; 1‑1050. < NLM ID: 8913266 > | Knapp W, Dorken B, Gilks W, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK (Eds): Leucocyte Typing IV. Oxford University Press, Oxford. 1989; 1‑1820. < NLM ID: 8914679 > | Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J Clin Pathol. 1993 Apr; 46(4):334‑6. < PMID: 7684403 > | Favaloro EJ, Browning T, Facey D: CD13 (GP150: aminopeptidase‑N): predominant functional activity in blood is localized to plasma and is not cell‑surface associated. Exp Hematol. 1993 Dec; 21(13):1695‑701. < PMID: 7902291 > | Tokuhara T, Hattori N, Ishida H, Hirai T, Higashiyama M, Kodama K, Miyake M: Clinical significance of aminopeptidase N in non‑small cell lung cancer. Clin Cancer Res. 2006 Jul 1; 12(13):3971‑8. < PMID: 16818694 > | Petrovic N, Schacke W, Gahagan JR, O'Conor CA, Winnicka B, Conway RE, Mina-Osorio P, Shapiro LH: CD13/APN regulates endothelial invasion and filopodia formation. Blood. 2007 Jul 1; 110(1):142‑50. < PMID: 17363739 > | Terauchi M, Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F: Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC Cancer. 2007 Jul 27; 7:140. < PMID: 17655775 > | McCormack E, Mujić M, Osdal T, Bruserud Ø , Gjertsen BT: Multiplexed mAbs: a new strategy in preclinical time‑domain imaging of acute myeloid leukemia. Blood. 2013 Feb 14; 121(7):e34‑42. < PMID: 23243270 >